Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors inside the central anxious method, conolidine modulates alternate molecular targets. A Science Improvements review found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://bertoltm826gif9.blogunok.com/profile